Equities

Stevanato Group SpA

Stevanato Group SpA

Actions
Health CareMedical Equipment and Services
  • Price (USD)20.42
  • Today's Change-0.14 / -0.68%
  • Shares traded140.97k
  • 1 Year change-30.90%
  • Beta0.6056
Data delayed at least 15 minutes, as of Nov 14 2024 20:31 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Stevanato Group SpA is an Italy-based manufacturer and distributor engaged in two segments: Biopharmaceutical and Diagnostic Solutions and Engineering, including the production and distribution of drug containment solutions, drug delivery systems, and diagnostic solutions in the pharmaceutical industry. The Company delivers products, processes, and services across all stages of drug developments, including pre-clinical, clinical, and commercialization. Its Engineering segment includes the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology, and diagnostic manufacturing processes. The Company operates locally, in Europe, and globally, including Brazil, China, Mexico, and the United States.

  • Revenue in USD (TTM)1.16bn
  • Net income in USD121.15m
  • Incorporated1949
  • Employees5.64k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Axonics Inc431.90m-5.66m3.60bn797.00--5.42527.818.34-0.108-0.1088.5213.000.6021.077.74541,909.70-0.7889-12.67-0.848-13.7676.5970.04-1.31-29.686.40--0.00--33.86249.0689.80--23.65--
Guardant Health Inc692.26m-512.41m3.91bn1.78k------5.64-4.24-4.245.70-0.4880.4153.687.81389,126.50-30.72-22.26-35.19-24.5960.3164.62-74.02-97.075.85-8.041.06--25.4544.1426.76--0.2786--
ICU Medical Inc2.30bn-70.79m4.27bn14.00k--2.1027.231.85-2.92-2.9294.9083.430.52672.1314.68164,591.20-1.621.46-1.831.6532.4734.11-3.072.231.080.55550.44120.00-0.915410.0460.08---1.45--
Integer Holdings Corp1.68bn114.44m4.61bn10.50k42.412.8520.852.753.243.2247.8748.330.55944.935.14160,023.803.813.284.103.5327.0626.946.816.402.094.110.40280.0016.035.6238.719.3321.71--
Haemonetics Corporation1.36bn123.81m4.70bn3.66k38.125.2620.133.452.412.4126.4817.440.60011.877.02372,224.005.465.026.196.0754.0251.749.108.112.0927.430.58230.0012.016.231.8716.40-11.04--
Procept Biorobotics Corp199.84m-100.06m4.99bn626.00--19.86--24.96-1.95-1.953.894.640.50261.833.86319,238.00-25.16---28.58--57.39---50.07--5.07--0.1758--81.55---21.51------
Inspire Medical Systems Inc755.59m33.05m5.46bn1.01k167.427.84143.657.231.091.0925.1523.251.052.469.37747,372.904.60-11.275.12-12.6084.7784.474.37-13.576.94--0.00--53.1965.3252.87--148.37--
Lantheus Holdings Inc1.50bn427.61m5.55bn834.0013.264.7011.323.706.026.0221.0916.970.83838.285.091,794,723.0023.956.6932.767.7364.7857.5628.579.021.56--0.3240.0038.6530.441,063.8651.8135.48--
Merit Medical Systems Inc1.33bn120.04m5.93bn6.95k49.814.4827.214.472.042.0422.5522.710.63342.297.41190,772.805.732.456.322.7746.8344.509.053.913.8231.880.36190.009.247.3326.7015.86-11.16--
Stevanato Group SpA1.16bn121.15m6.23bn5.64k45.574.0230.525.390.45120.45124.295.120.52842.752.66205,089.005.54--7.39--29.20--10.48--1.2148.530.2148--10.34--1.95------
Glaukos Corp360.35m-149.57m7.90bn907.00--11.81--21.92-2.96-2.967.0612.130.38431.697.53397,295.50-15.95-8.73-17.23-9.3576.6174.77-41.51-28.694.71-311.240.1591--11.2611.66-35.75--14.44--
Repligen Corp622.64m-17.13m8.43bn1.78k----245.6213.53-0.3079-0.307911.09--------349,206.40--4.38--5.0349.9655.43-2.7515.91------0.00-20.3126.91-77.6420.1324.99--
Henry Schein, Inc.12.50bn314.00m8.45bn25.00k27.742.4214.270.67572.442.4496.8927.991.224.777.73499,960.002.976.094.8610.4431.5930.042.424.400.8176.230.3480.00-2.445.55-22.68-0.145621.27--
Bruker Corp3.24bn304.90m8.47bn9.71k26.964.6917.932.612.072.0721.8911.920.65271.515.73333,913.706.128.388.1411.4049.3149.859.3811.390.708526.830.55499.8117.149.3644.0318.9116.794.56
Masimo Corp2.04bn78.60m8.66bn3.80k111.205.9149.954.241.451.4537.7227.350.67151.775.52537,526.302.588.653.2310.3150.0557.303.8512.031.112.840.34560.000.604219.00-43.21-15.9631.06--
Data as of Nov 14 2024. Currency figures normalised to Stevanato Group SpA's reporting currency: US Dollar USD

Institutional shareholders

61.74%Per cent of shares held by top holders
HolderShares% Held
Conestoga Capital Advisors LLCas of 30 Sep 20247.68m15.52%
Neuberger Berman Investment Advisers LLCas of 30 Jun 20244.55m9.20%
T. Rowe Price Investment Management, Inc.as of 30 Jun 20243.64m7.35%
Thrivent Asset Management LLCas of 30 Sep 20242.78m5.63%
Wellington Management Co. LLPas of 30 Sep 20242.69m5.44%
Jackson Square Partners LLCas of 30 Jun 20242.22m4.48%
Sands Capital Management LLCas of 30 Jun 20241.80m3.63%
Lazard Asset Management LLCas of 30 Jun 20241.77m3.58%
Artisan Partners LPas of 30 Jun 20241.76m3.55%
BAMCO, Inc.as of 30 Jun 20241.66m3.36%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.